Red Light Holland's subsidiary Filament Health has signed an agreement with GHU Paris Psychiatrie & Neurosciences to supply its patented botanical psilocybin drug candidate, PEX010, for a clinical study comparing the effects of ketamine and psilocybin on healthy volunteers. This randomized, double-blind, cross-over trial aims to deepen understanding of psilocybin's behavioral and neural impact, complementing patient trials. The deal expands Filament's international research presence to France and underscores Red Light Holland's commitment to supporting regulated, quality-controlled psychedelic research. PEX010 is already supplied to over 80 studies worldwide, making it a leading botanical psilocybin candidate in clinical research.
